These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 3804906)

  • 1. Oral ciprofloxacin therapy of infection caused by multiply resistant bacteria other than Pseudomonas aeruginosa.
    Scully BE; Neu HC
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():179-85. PubMed ID: 3804906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis.
    Hessen MT; Ingerman MJ; Kaufman DH; Weiner P; Santoro J; Korzeniowski OM; Boscia J; Topiel M; Bush LM; Kaye D
    Am J Med; 1987 Apr; 82(4A):262-5. PubMed ID: 3555045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria.
    Preheim LC; Cuevas TA; Roccaforte JS; Mellencamp MA; Bittner MJ
    Am J Med; 1987 Apr; 82(4A):295-300. PubMed ID: 3555051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral ofloxacin therapy of infections due to multiply-resistant bacteria.
    Scully BE; Clynes N; Neu HC
    Diagn Microbiol Infect Dis; 1991; 14(5):435-41. PubMed ID: 1797458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the treatment with oral ciprofloxacin: experience with 24 patients].
    Parras F; Torroba L; Buzón L; Martínez-Beltrán J; Loza E; Baquero F
    Enferm Infecc Microbiol Clin; 1989 May; 7(5):261-5. PubMed ID: 2490722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial.
    Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Screen P; Becker N; August R
    J Clin Pharmacol; 1988 Feb; 28(2):179-89. PubMed ID: 3360968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections.
    Fass RJ; Plouffe JF; Russell JA
    Am J Med; 1989 Nov; 87(5A):164S-168S. PubMed ID: 2589361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous/oral ciprofloxacin therapy of infections caused by multiresistant bacteria.
    Neu HC; Davidson S; Briones F
    Am J Med; 1989 Nov; 87(5A):209S-212S. PubMed ID: 2511758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of intravenous ciprofloxacin in difficult-to-treat infections.
    Giamarellou H; Galanakis N
    Am J Med; 1987 Apr; 82(4A):346-51. PubMed ID: 3555059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
    Fernandes PB; Chu DT; Bower RR; Jarvis KP; Ramer NR; Shipkowitz N
    Antimicrob Agents Chemother; 1986 Feb; 29(2):201-8. PubMed ID: 3521473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciprofloxacin in patients with bacteremic infections. The Spanish Group for the Study of Ciprofloxacin.
    Bouza E; Díaz-López MD; Bernaldo de Quirós JC; Rodríguez-Créixems M
    Am J Med; 1989 Nov; 87(5A):228S-231S. PubMed ID: 2589366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin.
    Scully BE; Jules K; Chin NX; Neu HC
    Am J Med; 1987 Apr; 82(4A):336-8. PubMed ID: 3578324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding.
    Sifuentes-Osornio J; Macías A; Amieva RI; Ramos A; Ruiz-Palacios GM
    Am J Med; 1989 Nov; 87(5A):202S-205S. PubMed ID: 2686425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral ciprofloxacin for treatment of acute bacterial pharyngotonsillitis.
    Esposito S; D'Errico G; Montanaro C
    J Chemother; 1990 Apr; 2(2):108-12. PubMed ID: 2113940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous ciprofloxacin for the treatment of severe infections.
    Santini C; Baiocchi P; Venditti M; Gelfusa V; Tarasi A; Brandimarte C; Serra P
    J Chemother; 1991 Apr; 3(2):121-5. PubMed ID: 1875231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections.
    Gaut PL; Carron WC; Ching WT; Meyer RD
    Am J Med; 1989 Nov; 87(5A):169S-175S. PubMed ID: 2686417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with ciprofloxacin in the USA.
    Arcieri G; August R; Becker N; Doyle C; Griffith E; Gruenwaldt G; Heyd A; O'Brien B
    Eur J Clin Microbiol; 1986 Apr; 5(2):220-5. PubMed ID: 2941286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of acute and chronic gram-negative osteomyelitis with ciprofloxacin. Report from a Swedish Study Group.
    J Antimicrob Chemother; 1988 Aug; 22(2):221-8. PubMed ID: 3053554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of serious infections with intravenous ciprofloxacin. French Multicenter Study Group.
    Modai J
    Am J Med; 1989 Nov; 87(5A):243S-247S. PubMed ID: 2686426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases.
    Ishikawa K; Hamasuna R; Uehara S; Yasuda M; Yamamoto S; Hayami H; Takahashi S; Matsumoto T; Minamitani S; Kadota J; Iwata S; Kaku M; Watanabe A; Sunakawa K; Sato J; Hanaki H; Tsukamoto T; Kiyota H; Egawa S; Deguchi T; Matsumoto M; Tanaka K; Arakawa S; Fujisawa M; Kumon H; Kobayashi K; Matsubara A; Wakeda H; Amemoto Y; Onodera S; Goto H; Komeda H; Yamashita M; Takenaka T; Fujimoto Y; Tsugawa M; Takahashi Y; Maeda H; Onishi H; Ishitoya S; Nishimura K; Mitsumori K; Ito T; Togo Y; Nakamura I; Ito N; Kanamaru S; Hirose T; Muranaka T; Yamada D; Ishihara S; Oka H; Inatomi H; Matsui T; Kobuke M; Kunishima Y; Kimura T; Ichikawa T; Kagara I; Matsukawa M; Takahashi K; Mita K; Kato M; Okumura K; Kawanishi H; Hashimura T; Aoyama T; Shigeta M; Koda S; Taguchi K; Matsuda Y
    J Infect Chemother; 2015 Sep; 21(9):623-33. PubMed ID: 26166322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.